GOSS Earnings & Financial Statements
Gossamer Bio, Inc.
$8.96
+$0.06(+0.62%)
27
Overall
40
Value
10
Tech
31
Quality
Market Cap
$54.47M
Volume
133.80K
52W Range
$9.10 - $309.60
Target Price
$82.48
GOSS earnings and financial statements: Gossamer Bio, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
GOSS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $48.47M | $114.70M | - | - | - |
| Operating income | -$170.73M | -$59.92M | -$183.76M | -$218.59M | -$216.12M |
| EBITDA | -$157.48M | -$38.88M | -$160.60M | -$209.91M | -$209.40M |
| Net income | -$170.37M | -$56.53M | -$179.82M | -$229.38M | -$234.00M |
| EPS (diluted) | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $172.25M | $315.29M | $311.92M | $272.45M | $343.66M |
| Total liabilities | $295.01M | $285.80M | $249.15M | $260.37M | $222.19M |
| Shareholders’ equity | -$122.76M | $29.49M | $62.77M | $12.08M | $121.46M |
| Cash and equivalents | $37.73M | $46.07M | $32.11M | $111.97M | $183.40M |
| Long-term debt | $3.46M | $4.40M | $958.0K | $15.43M | $32.30M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$171.27M | -$3.47M | -$159.16M | -$187.03M | -$188.89M |
| Capital expenditure | -$79.0K | - | - | -$475.0K | -$1.62M |
| Free cash flow | -$171.34M | -$3.47M | -$159.16M | -$187.51M | -$190.51M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GOSS | $8.96 | +0.6% | 133.80K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |